Table 2.
Blood test data
| Parameters | LVAD (n = 15) | HF (n = 12) | Normal range | p |
|---|---|---|---|---|
| vWF antigen (IU/dL) | 137 ± 14.5 | 147 ± 11.7 | 50–200 | 0.611 |
| vWF activity (IU/dL) | 90 ± 11 | 132.6 ± 13 | 50–200 | 0.017 |
| [vWF activity]/[vWF antigen] ratio | 0.65 ± 0.02 | 0.92 ± 0.06 | >0.60 | 0.001 |
| ADAMTS13 (%) | 80.3 ± 4.7 | 96.2 ± 3.5 | >40 | 0.016 |
| Factor VIII (%) | 173 ± 16 | 167.4 ± 16 | 55–205 | 0.813 |
| Fibrinogen (mg/dL) | 408.4 ± 23.4 | 371 ± 23.2 | 160–400 | 0.272 |
| D-dimers (ng/mL FEU) | 3217.7 ± 735 | 680.6 ± 223.2 | <500 | 0.006 |
| vWF multimer deficit levels | 3/15 | 1/12 | NA | 0.396 |
| Blood group “O” (% of patients) | 33 | 41 | NA | 0.683 |
| Platelet count (109/L) | 237 ± 25 | 207 ± 20 | 150–450 | 0.373 |
| INR | 2.6 ± 0.2 | 1.4 ± 0.2 | 0.8–1.2 | 0.001 |
| aPTT (sec) | 34.4 ± 1.2 | 26.5 ± 1.3 | 24–35 | 0.001 |
| PT (%) | 28.8 ± 3.5 | 78.2 ± 9.8 | 70–130 % | 0.001 |
| CRP | 14.1 ± 3.8 | 6.45 ± 2 | <10 | 0.108 |
| Bilirubin total | 0.58 ± 0.07 | 0.68 ± 0.1 | <1.2 | 0.448 |
| Alkaline Phosphatase | 95.3 ± 15.2 | 77.7 ± 11.6 | 56–119 | 0.383 |
| ALT (SGPT) | 23.3 ± 3.85 | 56 ± 21.8 | <45 | 0.113 |
| AST (SGOT) | 21.4 ± 1.35 | 47.4 ± 19.4 | <35 | 0.146 |
| Multiplate analysis | ||||
| Ristocetin 1 mg/mL (U) | 61 ± 8.2 | 92.6 ± 9.7 | 90–201 | 0.019 |
| Adenosine diphosphate (U) | 62.3 ± 6.3 | 73.7 ± 8.7 | 53–122 | 0.285 |
| Thrombin receptor activating peptide-6 (U) | 93.7 ± 5.6 | 113.8 ± 6.5 | 94–156 | 0.028 |
| Arachidonic acid (U) | 33.1 ± 7.6 | 60.7 ± 8.5 | 75–136 | 0.024 |
| Collagen binding activity assay (U) | 43.1 ± 4.6 | 62.8 ± 5.8 | 46–117 | 0.012 |
| Spontaneous (U) | 10 ± 2.3 | 14.3 ± 2.5 | 1–25 | 0.226 |
INR international normalized ratio, aPTT activated partial thromboplastin time, PT prothrombin time, CRP C-Reactive Protein, ALT alanine aminotransferase, AST aspartate aminotransferase, NA not applicable